Impact of an interatrial shunt device on survival and heart failure hospitalization in patients with preserved ejection fraction

26 May 2018 (00:00 - 00:00)

Organised by:

Sign in to view the resources

About the speaker

Professor David Kaye

Baker Heart and Diabetes Institute, Melbourne (Australia)

6 More presentations in this session

Presentation thumbnail

Surfactant proteins changes after acute hemodynamic improvement in patients with advanced chronic heart failure treated with levosimendan

Doctor M. Mapelli (Milan, IT)

Abstract Slides

Presentation thumbnail

Stanford integrated psychosocial assessment for transplantation scores track with intermacs profile and predict readmissions in patients undergoing left ventricular assist device implantation

Doctor M. Cagliostro (New York, US)

Abstract Slides

Presentation thumbnail

What happened to patients being listed for Heart Transplantation who did not arrive to Transplantation? Reasons for coming out of the waiting list and long term follow-up

Doctor M. Castel Lavilla (Barcelona, ES)

Abstract Slides

Presentation thumbnail

Prognosis of patients with cardiac amyloidosis referred in the French national referral Centre for Cardiac Amyloidosis

Doctor D. Bodez (Creteil, FR)

Presentation thumbnail

Angiotensin based biomarkers predict outcome in HFpEF-patients

Doctor C. Binder (Vienna, AT)

Access the full session

Session thumbnail

Moderated Poster session 5 - Advanced heart failure

The Event

Heart Failure 2018

26 May - 29 May 2018

You may be interested in

Congress Presentation

Distinguishing heart failure with reduced ejection fraction from heart failure with preserved ejection fraction: a phenomics approach.

Congress Presentation

Pharmacotherapy in HFpEF: where do cardiometabolic drugs fit in?

Congress Session

Clinical phenotypes of heart failure with preserved ejection fraction

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources